泽璟制药(688266.SH)：注射用ZGGS34获得药物临床试验批准通知书

Core Viewpoint - Zai Lab has received approval from the National Medical Products Administration for clinical trials of ZGGS34, a drug targeting MUC17-positive advanced solid tumors, indicating progress in its oncology pipeline [1] Group 1: Drug Approval and Clinical Trials - The company has obtained the Clinical Trial Approval Notice for ZGGS34, which is intended for use in MUC17-positive advanced solid tumors [1] - The approval marks a significant step in the development of ZGGS34, allowing the company to proceed with clinical trials [1] Group 2: Preclinical Research Findings - Preclinical studies have demonstrated that ZGGS34 exhibits significant tumor suppression effects across various tumor models, leading to tumor regression [1] - The drug has shown strong tumor-killing properties, suggesting its potential efficacy in treating advanced solid tumors [1] - Toxicology studies conducted in non-human primates indicate that ZGGS34 possesses favorable safety characteristics [1]